UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval

RegulatoryNegative

AI Analysis

Summary

Unicycive Therapeutics (UNCY) experienced its worst trading day in a year following news of a 5-12 month delay in drug approval, though analysts maintained buy ratings despite the setback.

Outcome Details

5-12 month delay in drug approval

Importance:6/10

Sentiment:

-0.75

regulatory delaystock declineapproval delayanalyst ratings

Related Companies

$UNCY

Read the original article

Published by yahoo_finance on June 30, 2026 9:34 PM

Read Original